Although hopes had not been high for the Phase II study in first-line non-small-cell lung cancer (NSCLC) to begin with, and the company – after talking with the FDA – still plans to go ahead with a Phase III trial, investors looked askance at Peregrine Pharmaceuticals Inc.'s latest snag with the cancer drug bavituximab. Read More
Obesity raises an individual's risk of developing a variety of different tumor types, but most of the details of how it does so remain unclear. Read More
TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong. Read More
Eleven Biotherapeutics Inc., of Cambridge, Mass., is celebrating successful completion of its Phase Ib/IIa study of EBI-005 in dry eye disease. Read More
• Ampliphi BioSciences Corp., of Seattle, completed a private placement of convertible preferred stock for gross proceeds of $7 million to advance bacteriophage products for bacterial infections. Read More
• Immune Design Inc., of Seattle, and Medicago Inc., of Quebec City, entered a license agreement providing Medicago the use and commercialization of Immune Design's synthetic Toll-like receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Read More
• Access Pharmaceuticals Inc., of Dallas, said top-line results from a Phase IV study showed that Mugard mucoadhesive oral wound rinse met the primary study endpoint, with patients receiving the product experiencing a statistically significant reduction vs. placebo in mouth and throat soreness. Read More
• Janssen Biotech Inc., of Spring House, Pa., part of Johnson & Johnson, of New Brunswick, N.J., and Johnson & Johnson Innovation established a research alliance with the Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next-generation therapeutic solutions. Read More
• Forest Laboratories Inc., of New York, reported top-line results from an eight-week pivotal Phase III trial of the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. Read More
